SEPN Stock Price | Septerna, Inc. Common Stock P/E, Revenue, EPS, & Forecasts

Septerna, Inc. Common Stock • SEPN

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Septerna, Inc. Common Stock

Ticker

SEPN

Trading on

NASDAQ

ISIN

US81734D1046

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Jeffrey T. Finer M.D., Ph.D.

Headquarters

250 East Grand Avenue, South San Francisco, CA, United States, 94080

Employees

Website

https://septerna.com

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. The company also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Metrics

BasicAdvanced

Market cap

$444M

P/E ratio

EPS

-$1.78

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-89.8M

Ex dividend date

Price & volume

Market cap

$444M

Average daily volume

0.5M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

454.7

Price to book

1.11

Earnings

EPS

-$1.78

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-89.8M

Revenues (TTM)

$1M

Revenues per share (TTM)

$0.05

Technicals

Beta

52-week High

$28.99

52-week Low

$4.17

50-day moving average

$6.55

200-day moving average

$14.29

Short ratio

13.41

Short %

12.40%

Management effectiveness

ROE (TTM)

-30.96%

ROA (TTM)

0.00%

Profit margin

0.00%

Gross profit margin

$1M

Operating margin

-11,831.05%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

-30.90%

Share stats

Outstanding Shares

44.6M

Float

18.2M

Insiders %

6.74%

Institutions %

102.92%

Analyst Insights & forecasts

75% Buy

25% Hold

0% Sell

Based on information from 4 analysts.

Average price target

$23.67

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$12.76

Q2 • 24Beat

-$4.62

Q3 • 24Beat

-$0.64

-$0.69

6.80%

Q4 • 24Beat

-$0.49

-$0.54

9.26%

Q1 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0.2M

$-20.7M

-9,749.06%

Q4 • 24

$0.2M

$-21.5M

-9,806.39%

Q1 • 25

3.30%

3.91%

0.59%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$457M

$36.5M

8.00%

Q4 • 24

$434M

$33.8M

7.78%

Q1 • 25

-4.94%

-7.54%

-2.74%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-21M

$-133M

$304M

$-21.6M

Q4 • 24

$-23.3M

$-4.9M

$0.1M

$-23.7M

Q1 • 25

11.38%

-96.34%

-99.98%

9.99%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Septerna, Inc. Common Stock share?

Septerna, Inc. Common Stock shares are currently traded for undefined per share.

How many shares does Septerna, Inc. Common Stock have?

Septerna, Inc. Common Stock currently has 44.6M shares.

Does Septerna, Inc. Common Stock pay dividends?

No, Septerna, Inc. Common Stock doesn't pay dividends.

What is Septerna, Inc. Common Stock 52 week high?

Septerna, Inc. Common Stock 52 week high is $28.99.

What is Septerna, Inc. Common Stock 52 week low?

Septerna, Inc. Common Stock 52 week low is $4.17.

What is the 200-day moving average of Septerna, Inc. Common Stock?

Septerna, Inc. Common Stock 200-day moving average is $14.29.

Who is Septerna, Inc. Common Stock CEO?

The CEO of Septerna, Inc. Common Stock is Dr. Jeffrey T. Finer M.D., Ph.D..

How many employees Septerna, Inc. Common Stock has?

Septerna, Inc. Common Stock has 75 employees.

What is the market cap of Septerna, Inc. Common Stock?

The market cap of Septerna, Inc. Common Stock is $444M.

What is the P/E of Septerna, Inc. Common Stock?

The current P/E of Septerna, Inc. Common Stock is null.

What is the EPS of Septerna, Inc. Common Stock?

The EPS of Septerna, Inc. Common Stock is -$1.78.

What is the PEG Ratio of Septerna, Inc. Common Stock?

The PEG Ratio of Septerna, Inc. Common Stock is null.

What do analysts say about Septerna, Inc. Common Stock?

According to the analysts Septerna, Inc. Common Stock is considered a buy.